3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
12
Dermatologic
10
Plasma cell
3
Lymphoid
3
Other hematologic neoplasm
2
Gastrointestinal
2
Thoracic
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Thyroid Neoplasms
5
Thyroid Cancer, Papillary
4
Thyroid Carcinoma, Anaplastic
2
Thyroid cancer, follicular
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Laryngeal Neoplasms
1
Heterotaxy Syndrome
1
Hematologic Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma, Follicular
1
Interventions
pembrolizumab
33
Cetuximab
16
Cisplatin
10
Radiotherapy
8
Paclitaxel
8
Docetaxel
8
atezolizumab
7
Fluorouracil
7
cemiplimab
6
Drug Therapy
6
budigalimab
5
Gemcitabine
5
Cyclophosphamide
5
Blood Specimen Collection
5
trametinib
4
Pemetrexed
4
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Bleomycin
4
Bevacizumab
4
palbociclib
3
fludarabine
3
durvalumab
3
dabrafenib
3
avelumab
3
Trastuzumab
3
Oxaliplatin
3
Interleukin-2
3
Indocyanine Green
3
Immunotherapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Vemurafenib
×
Head & Neck
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled